FDA Approval: Adjuvant Alectinib for Resected NSCLC

In the wake of the FDA's approval of alectinib for resected non-small cell lung cancer, Lung Cancer Considered host Dr. Narjust Florez and Dr. Benjamen Solomon discuss this development and take a deeper look at the ALINA trial, which included patients with resected stage II/III NSCLC with an ALK fusion.